FI973235A0 - Menetelmä IL-6:n vaikutusten inhiboimiseksi - Google Patents

Menetelmä IL-6:n vaikutusten inhiboimiseksi

Info

Publication number
FI973235A0
FI973235A0 FI973235A FI973235A FI973235A0 FI 973235 A0 FI973235 A0 FI 973235A0 FI 973235 A FI973235 A FI 973235A FI 973235 A FI973235 A FI 973235A FI 973235 A0 FI973235 A0 FI 973235A0
Authority
FI
Finland
Prior art keywords
inhibiting
effects
Prior art date
Application number
FI973235A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI973235A7 (fi
FI973235L (fi
Inventor
Andrew L Glasebrook
Steven H Zuckerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI973235A7 publication Critical patent/FI973235A7/fi
Publication of FI973235L publication Critical patent/FI973235L/fi
Publication of FI973235A0 publication Critical patent/FI973235A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
FI973235A 1995-02-06 1996-02-05 Menetelmä IL-6:n vaikutusten inhiboimiseksi FI973235A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38473095A 1995-02-06 1995-02-06
PCT/US1996/001621 WO1996024356A1 (en) 1995-02-06 1996-02-05 Methods of inhibiting effects of il-6

Publications (3)

Publication Number Publication Date
FI973235A7 FI973235A7 (fi) 1997-08-05
FI973235L FI973235L (fi) 1997-08-05
FI973235A0 true FI973235A0 (fi) 1997-08-05

Family

ID=23518514

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973235A FI973235A0 (fi) 1995-02-06 1996-02-05 Menetelmä IL-6:n vaikutusten inhiboimiseksi

Country Status (14)

Country Link
EP (1) EP0724879A2 (enExample)
JP (1) JPH10513470A (enExample)
KR (1) KR19980701933A (enExample)
CN (1) CN1173819A (enExample)
AU (1) AU708374B2 (enExample)
CA (1) CA2212232A1 (enExample)
CZ (1) CZ246597A3 (enExample)
FI (1) FI973235A0 (enExample)
HU (1) HUP9801829A3 (enExample)
IL (1) IL117036A0 (enExample)
NO (1) NO973609L (enExample)
WO (1) WO1996024356A1 (enExample)
YU (1) YU6996A (enExample)
ZA (1) ZA96897B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
KR20020009383A (ko) 1998-04-01 2002-02-01 우에노 도시오 축합 티오펜 유도체 및 이의 유도체를 유효 성분으로 하는약제
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
ES2207982T3 (es) * 1998-12-30 2004-06-01 Signal Pharmaceuticals, Inc. Compuestos y metodos para la modulacion de receptores estrogenicos.
ES2156550B1 (es) * 1999-04-19 2002-02-01 Univ Navarra Publica Derivados de benzo(b) tiofenosulfonamida-1,1-dioxido y su uso como agentes antineoplasicos.
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
RU2005125043A (ru) * 2003-01-06 2006-01-27 Уайт (Us) Применение модуляторов альфа-рецепторов эстрогена для лечения рассеянного склероза

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW303299B (enExample) * 1993-07-22 1997-04-21 Lilly Co Eli
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5521198A (en) * 1993-12-21 1996-05-28 Eli Lilly And Company Methods of inhibiting autoimmune diseases
US5567820A (en) * 1994-05-20 1996-10-22 Eli Lilly And Company Glucopyranoside benzothiophenes

Also Published As

Publication number Publication date
EP0724879A2 (en) 1996-08-07
FI973235A7 (fi) 1997-08-05
KR19980701933A (ko) 1998-06-25
NO973609L (no) 1997-09-11
ZA96897B (en) 1997-08-05
WO1996024356A1 (en) 1996-08-15
NO973609D0 (no) 1997-08-05
FI973235L (fi) 1997-08-05
EP0724879A3 (enExample) 1996-09-11
MX9705940A (es) 1997-10-31
HUP9801829A3 (en) 1999-10-28
JPH10513470A (ja) 1998-12-22
IL117036A0 (en) 1996-06-18
CA2212232A1 (en) 1996-08-15
AU4916396A (en) 1996-08-27
AU708374B2 (en) 1999-08-05
HUP9801829A2 (hu) 1999-05-28
CN1173819A (zh) 1998-02-18
CZ246597A3 (cs) 1998-06-17
YU6996A (sh) 1999-03-04

Similar Documents

Publication Publication Date Title
FI951596L (fi) Menetelmä 10-desasetyylibakkatiini-III:n saamiseksi
FI923421L (fi) Menetelmä siementen päällystämiseksi
NO973009D0 (no) Fremgangsmåte for å inhibere kathepsin-k
DE69534965D1 (de) Abscheidungsverfahren
DE69636449D1 (de) Armbanduhr-funktelefon
DE69621026D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
ID16345A (id) Senyawa-senyawa heterosiklik
FI945441L (fi) Uusi menetelmä 7beta-substituoitu-4-atsa-5alfa-androstan-3-onien valmistamiseksi
FI944619A7 (fi) Aldolisointi-dehydratointimenetelmä
FI973281L (fi) Menetelmä tiettyjen atsasykloheksapeptidien valmistamiseksi
FI972764A7 (fi) Menetelmä liuosten muodostamiseksi
PT858464E (pt) Inibidores de trombina
BR9600251A (pt) Composto
KR970001365A (ko) 알킬하이드로겐클로로실란의 제조방법
NO981242D0 (no) Ett-löps stigerör
NO974169D0 (no) Fremgangsmåte for tetra-azacykloalkan-fremstilling
FI921621L (fi) Sprutmetod foer braensle
IS4739A (is) Efnasambönd
DE59601268D1 (de) Uhrenarmband
NO974170D0 (no) Polyazacykloalkan-forbindelser
FI973235L (fi) Menetelmä IL-6:n vaikutusten inhiboimiseksi
BR9601295A (pt) Composto
IS4285A (is) Aðferð við að hindra útfellingu
FI971675A0 (fi) Menetelmä bradykiniinin liittyvien tilojen inhiboimiseksi
BR9611576A (pt) Composto